Chikungunya test vaccine shows promise: makers基孔肯雅熱疫苗試驗表明承諾:製造商

August 16, 2014, 12:02 am TWN

PARIS -- A candidate vaccine against the joint disease chikungunya, endemic to Africa and south Asia but moving north- and westward, showed promise by provoking an immune response in human trials, its developers said Friday.

The trial drug is made with nanoparticles that resemble a West African strain of the virus, which causes high fever and intensely painful arthritis, said a study in The Lancet medical journal.

These virus-like particles (VLPs) are meant to mimic the immune-stimulating effects of the actual virus particles, but cannot cause disease as they contain no viral DNA.

In tests on rhesus macaques, the vaccine provided protection from infection and its first human tests have now also yielded positive results.

“All injections were well tolerated, with no serious adverse events reported,” wrote the authors of the study.

Antibodies are protective proteins produced by the immune system in response to foreign agents like viruses.

“Eleven months after vaccination, antibody levels were comparable to those seen in people who had recovered after natural chikungunya infection, suggesting that the ... vaccine could provide long-term protection against the virus,” said study co-author Julie Ledgerwood of the U.S.-based National Institutes of Health.

Europe reported its first locally transmitted case of the mosquito-borne illness in 2007, in Italy.

The disease was first noted in the Western Hemisphere in December, and the United States had its first home-grown case last month.

There is no vaccine to prevent the disease and no medicine to treat it but a number of vaccines are at different stages of testing.

Ledgerwood said a VLP vaccine should be “relatively economical” to produce in large quantities.

But Ann Powers from the U.S.-based Centers for Disease Control and Prevention wrote in a comment: “The market might not be large enough to justify the investment.”

The cost of developing a vaccine, from preclinical studies to registration, was about US$200-US$500 million, she said.



巴黎 - 對關節病基孔肯雅熱,特有的非洲和南亞,但移動的北部和西候選疫苗,顯露才華挑起的人體試驗的免疫反應,它的開發者說,星期五。














    evita6804 發表在 痞客邦 留言(0) 人氣()